Nanocurcumin for the treatment of attention-deficit/hyperactivity disorder

Nanocurcumin adjunct to methylphenidate for attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N168

Enrollment

Registered

2026-02-11

Start date

2026-02-20

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD. Attention-deficit hyperactivity disorder, combined type

Interventions

Intervention 1: Control group: Individuals receive methylphenidate (The dose will be adjusted based on standard clinical principles and tailored to the patient's weight and clinical response, within t

Eligibility

Sex/Gender

All

Age

6 Years to 17 Years

Inclusion criteria

Inclusion criteria: ADHD diagnosis based on DSM5 Individuals between 6-17 years old

Exclusion criteria

Exclusion criteria: Presence of severe medical illness, neurological problems and problems requiring surgery Presence of any concomitant psychiatric disorder that requires treatment with psychiatric drugs except ODD Consumption neuroleptic medication in the last 6 months Weight less than 13.5 kg Mental retardation Uncontrolled seizure disorder Systolic blood pressure above 125 mm Hg or Resting pulse rate less than 60 beats per minute or above 115 beats per minute Using any medicine or supplement for the treatment of ADHD

Design outcomes

Primary

Measure	Time frame
Severity of ADHD symptoms. Timepoint: Week 0 - 5 - 10. Method of measurement: By ADHD Rating Scale (by parents and teacher).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026